Racagni Giorgio, Popoli Maurizio
Center of Neuropharmacology, Department of Pharmacological Sciences and Center of Excellence on Neurodegenerative Diseases, University of Milano, Italy.
Dialogues Clin Neurosci. 2008;10(4):385-400. doi: 10.31887/DCNS.2008.10.4/gracagni.
The hypotheses on the pathophysiology of depression/mood disorders and on antidepressant mechanisms have greatly changed in recent years. The classical monoamine hypothesis was revealed to be simplistic, in that it could not explain the temporal delay in the therapeutic action of antidepressants. Converging lines of evidence have shown that adaptive changes in the several mechanisms of neuroplasticity are likely to be the cellular and molecular correlates of therapeutic effect. In this article, several mechanisms of neuroplasticity are analyzed in relation to the mechanism of antidepressants, ranging from changes in gene expression (including neurotrophic mechanisms), to synaptic transmission and plasticity, and neurogenesis. We propose that the current version of the hypothesis of antidepressant mechanism simply be called the "hypothesis of neuroplasticity". In the final section, we also briefly review the main current novel strategies in the pharmacology of depression and the new putative targets for antidepressants, with particular emphasis on nonmonoaminergic mechanisms.
近年来,关于抑郁症/情绪障碍的病理生理学以及抗抑郁机制的假说发生了很大变化。经典的单胺假说被证明过于简单,因为它无法解释抗抑郁药治疗作用的时间延迟。越来越多的证据表明,神经可塑性的多种机制中的适应性变化可能是治疗效果的细胞和分子关联。在本文中,我们分析了几种与抗抑郁药机制相关的神经可塑性机制,范围从基因表达的变化(包括神经营养机制)到突触传递和可塑性以及神经发生。我们建议将当前版本的抗抑郁机制假说简称为“神经可塑性假说”。在最后一部分,我们还简要回顾了当前抑郁症药理学中的主要新策略以及抗抑郁药的新潜在靶点,特别强调了非单胺能机制。